Título:	Antitumor activity of photodynamic therapy performed with nanospheres containing zinc-phthalocyanine
Autor(es):	Portilho, Flávia Arruda Cavalcanti, Cláudio Eduardo de Oliveira Miranda-Vilela, Ana Luisa Estevanato, Luciana Landim Carneiro Longo, João Paulo Figueiró Santos, Maria de Fátima Menezes Almeida Bocca, Anamélia Lorenzetti Martins, Olímpia Paschoal Simioni, Andreza Ribeiro Morais, Paulo César Azevedo, Ricardo Bentes de Tedesco, Antonio Claudio Lacava, Zulmira Guerrero Marques
Assunto:	Câncer - tratamento Terapia fotodinâmica Testes
Data de publicação:	16-Dez-2013
Editora:	BioMed Central
Referência:	PORTILHO, Flávia Arruda. et al. Antitumor activity of photodynamic therapy performed with nanospheres containing zinc-phthalocyanine. BioMed Central, v. 10, Article 41, 16 dez. 2013. Disponível em <https://jnanobiotechnology.biomedcentral.com/articles/10.1186/1477-3155-11-41>. Acesso em: 9 jun. 2017. doi: https://jnanobiotechnology.biomedcentral.com/articles/10.1186/1477-3155-11-41.
Abstract:	Background: The increasing incidence of cancer and the search for more effective therapies with minimal collateral effects have prompted studies to find alternative new treatments. Among these, photodynamic therapy (PDT) has been proposed as a very promising new modality in cancer treatment with the lowest rates of side effects, revealing itself to be particularly successful when the photosensitizer is associated with nanoscaled carriers. This study aimed to design and develop a new formulation based on albumin nanospheres containing zinc-phthalocyanine tetrasulfonate (ZnPcS4-AN) for use in the PDT protocol and to investigate its antitumor activity in Swiss albino mice using the Ehrlich solid tumor as an experimental model for breast cancer. Methods: Ehrlich tumor’s volume, histopathology and morphometry were used to assess the efficacy of intratumoral injection of ZnPcS4-AN in containing tumor aggressiveness and promoting its regression, while the toxicity of possible treatments was assessed by animal weight, morphological analysis of the liver and kidneys, hemogram, and serum levels of total bilirubin, direct bilirubin, indirect bilirubin, aspartate aminotransferase (AST), alanine aminotransferase (ALT), gamma glutamyl transferase (GGT), alkaline phosphatase, creatinine and urea. In order to evaluate the efficacy of PDT, groups of animals treated with intratumoral injection of doxorubicin (Dox) were also investigated. Results: Intratumoral injection of ZnPcS4-AN was found to be efficient in mediating PDT to refrain tumor aggressiveness and to induce its regression. Although tumor volume reduction was not significant, PDT induced a remarkable increase in the necrosis area seen in the tumor’s central region, as in other experimental groups, including tumor and Dox treated groups, but also in the tumor’s peripheral region. Further, PDT showed minimal adverse effects. Indeed, the use of ZnPcS4-AN in mediating PDT revealed anti-neoplastic activity similar to that obtained while using intratumoral Dox therapy. Conclusions: PDT mediated by the new formulation ZnPcS4-AN enhanced the inhibition of tumor growth while producing practically no adverse effects and thus emerges as a very promising nanotechnology-based strategy for solid cancer treatment.
Licença:	© 2013 Portilho et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
DOI:	https://dx.doi.org/10.1186/1477-3155-11-41
Aparece nas coleções:	Artigos publicados em periódicos e afins

Os itens no repositório estão protegidos por copyright, com todos os direitos reservados, salvo quando é indicado o contrário.